Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study

Trial Profile

Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2019

At a glance

  • Drugs Memantine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 07 Aug 2019 Results assessing effects of on cognition and negative symptoms of a 6- or 24-week memantine add-on treatment to risperidone in patients with acute or chronic schizophrenia published in the Pharmacopsychiatry
    • 17 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2012 Planned End Date changed from 1 Apr 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top